RecruitingNCT05125939

Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study

Improving Colonoscopy Adenoma Detection Metrics by Extending the Screening-only Measurement to All Indications: a Prospective Multicenter Study


Sponsor

Evergreen General Hospital, Taiwan

Enrollment

2,700 participants

Start Date

Nov 20, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This is a prospective equivalence colonoscopy study evaluating whether overall adenoma detection rate (ADR) is a reliable alternate for screening ADR. Overall indication includes screening, surveillance, and diagnostic indications.


Eligibility

Min Age: 50 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Comparison of ADR for people with adenoma detection rate and colonoscopy. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 50 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERComparison of ADR

The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.


Locations(6)

Sepulveda Ambulatory Care Center, VAGLAHS

North Hills, California, United States

E-Da Dachang Hospital

Kaohsiung City, Taiwan

E-Da Hospital

Kaohsiung City, Taiwan

Keelung Chang Gung Memorial Hospital

Keelung, Taiwan

Evergreen General Hospital

Taoyuan, Taiwan

Linkou Chang Gung Memorial Hospital

Taoyuan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05125939


Related Trials